{"generic":"Monoctanoin","drugs":["Moctanin","Monoctanoin"],"mono":{"0":{"id":"381190-s-0","title":"Generic Names","mono":"Monoctanoin"},"1":{"id":"381190-s-1","title":"Dosing and Indications","sub":[{"id":"381190-s-1-4","title":"Adult Dosing","mono":"<b>Gallstone:<\/b> 2-3 mL\/hr via biliary tract perfusion; may increase the infusion rate if minimal or no gallstone dissolution occurs for approximately 5 days (MAX rate 5 mL\/hr)"},{"id":"381190-s-1-5","title":"Pediatric Dosing","mono":"Safety and effectiveness have not been established in children"},{"id":"381190-s-1-6","title":"Dose Adjustments","mono":"<b>liver disease:<\/b> may need to use lower doses in patients with impaired hepatic function; do not use in patients with severe hepatic dysfunction"},{"id":"381190-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Gallstone<br\/>"}]},"3":{"id":"381190-s-3","title":"Contraindications\/Warnings","sub":[{"id":"381190-s-3-9","title":"Contraindications","mono":"<ul><li>clinical jaundice, significant biliary tract infection, or recent history of duodenal ulcer or jejunitis<\/li><li>not for parenteral use; intended for biliary tract perfusion<\/li><\/ul>"},{"id":"381190-s-3-10","title":"Precautions","mono":"<ul><li>cholesterol composition of stones should be confirmed prior to treatment<\/li><li>discontinue treatment if fever, anorexia, chills, leukocytosis, severe right upper quadrant abdominal pain, or jaundice occur<\/li><li>may be irritating to the gastrointestinal and biliary tracts, and may cause ascending cholangitis<\/li><li>sensitivity to monoctanoin or vegetable oils (cross-sensitivity)<\/li><li>should not be used in the presence of impaired hepatic function, portosystemic shunting, or acute pancreatitis<\/li><li>there must be no obstruction distal to the stone which would impede passage of the solvent into the intestine and the duct should be intact, ie, dye entering the duct should not extravasate into the peritoneal cavity<\/li><\/ul>"},{"id":"381190-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"381190-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"381190-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Shivering (1-6%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (40%), Diarrhea (5.5-16%), Nausea (11-25%), Vomiting (3-15%)<\/li><li><b>Other:<\/b>Fever<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure (rare)<\/li><li><b>Gastrointestinal:<\/b>Duodenal ulcer disease (rare), Duodenitis, Pancreatitis, acute (rare)<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction (rare)<\/li><li><b>Renal:<\/b>Renal failure (rare)<\/li><li><b>Respiratory:<\/b>Pulmonary embolism (rare)<\/li><\/ul>"},"6":{"id":"381190-s-6","title":"Drug Name Info","sub":{"0":{"id":"381190-s-6-17","title":"US Trade Names","mono":"Moctanin<br\/>"},"2":{"id":"381190-s-6-19","title":"Class","mono":"Gastrointestinal Agent<br\/>"},"3":{"id":"381190-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"381190-s-7","title":"Mechanism Of Action","mono":"Local: Cholelitholytic; solubilizing agent (cholesterol)-Physical dissolution of cholesterol stones.  <br\/>"},"8":{"id":"381190-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"381190-s-8-25","title":"Metabolism","mono":"Local: Biliary: extensive metabolism to fatty acids and glycerol <br\/>"}}},"9":{"id":"381190-s-9","title":"Administration","mono":"<b>Injection, biliary tract<\/b><br\/><ul><li>a peristaltic infusion pump should be utilized to infuse the drug into the biliary tract by T-tube or nasobiliary catheter<\/li><li>administration of monoctanoin may be interrupted during meals<\/li><li>monoctanoin should be warmed to 60-80 degrees F prior to perfusion; the temperature of the perfusate should be kept at 98.6 degrees F (37 degrees C) during administration<\/li><li>not approved for perfusion by other routes such as into the gallbladder following cholecystectomy or into the liver via percutaneous transhepatic catheter<\/li><li>not for parenteral use; intended for biliary tract perfusion<\/li><li>should only be administered by persons experienced in perfusion therapy<\/li><li>use an overt flow manometer to ensure that perfusion pressure does not exceed 15 cm of water<\/li><\/ul>"},"10":{"id":"381190-s-10","title":"Monitoring","mono":"<ul><li>liver function tests should be routinely monitored and progress of stone dissolution in most patients should be monitored by performing repeat cholangiograms at 5-7 day intervals<\/li><li>discontinue therapy if endoscopy or x-ray do not show elimination or reduction in size of stones after 10 days<\/li><\/ul>"},"13":{"id":"381190-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea and vomiting.<\/li><li>Advise patient to immediately report occurrence of fever, anorexia, chills, severe right upper quadrant abdominal pain, or jaundice.<\/li><\/ul>"}}}